Umberto Capitanio Selected Research

Immunotherapy

11/2023	Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study.
1/2023	The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
1/2022	Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
5/2021	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.
1/2021	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
1/2021	Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.
1/2020	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Umberto Capitanio Research Topics

Disease

109	Neoplasms (Cancer) 05/2024 - 04/2008
87	Renal Cell Carcinoma (Grawitz Tumor) 05/2024 - 11/2008
53	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 07/2008
23	Kidney Neoplasms (Kidney Cancer) 12/2023 - 12/2011
20	Neoplasm Metastasis (Metastasis) 05/2024 - 04/2009
19	Carcinoma (Carcinomatosis) 02/2022 - 01/2009
18	Urinary Bladder Neoplasms (Bladder Cancer) 10/2021 - 05/2009
17	Margins of Excision 10/2022 - 10/2008
14	Chronic Renal Insufficiency 05/2024 - 10/2016
9	Lymphatic Metastasis 09/2021 - 10/2008
8	Acute Kidney Injury (Acute Renal Failure) 12/2023 - 01/2019
8	Ischemia 10/2023 - 01/2019
6	Thrombosis (Thrombus) 04/2024 - 01/2018
6	Intraoperative Complications 11/2022 - 10/2018
6	Disease Progression 01/2022 - 01/2009
5	Erectile Dysfunction 03/2017 - 09/2008
4	Frailty 01/2023 - 03/2020
4	Necrosis 11/2022 - 04/2010
4	Hypertension (High Blood Pressure) 02/2022 - 10/2016
4	Lower Urinary Tract Symptoms 01/2019 - 09/2008
3	Chronic Kidney Failure (Chronic Renal Failure) 11/2021 - 10/2016
3	Carcinoma in Situ 05/2012 - 01/2010
3	Residual Neoplasm 02/2011 - 07/2008
2	Solitary Kidney 01/2023 - 01/2018
2	Overweight 01/2020 - 03/2012
2	Hyperplasia 01/2019 - 04/2014
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019 - 02/2011
2	Hypogonadism (Hypergonadotropic Hypogonadism) 04/2013 - 09/2011
2	Lymphocele 09/2011 - 04/2011
2	Extranodal Extension 09/2011 - 04/2011
2	Rectal Neoplasms (Rectal Cancer) 10/2010 - 02/2010
2	Renal Insufficiency (Renal Failure) 02/2010 - 06/2009
1	Malnutrition (Nutritional Deficiencies) 05/2024
1	Morbid Obesity 10/2023
1	renal Oncocytoma 09/2023
1	Rare Diseases (Rare Disease) 10/2022
1	COVID-19 01/2022

Drug/Important Bio-Agent (IBA)

18	pembrolizumabIBA 11/2023 - 01/2020
13	Prostate-Specific Antigen (Semenogelase)IBA 09/2014 - 07/2008
7	AndrogensIBA 12/2018 - 08/2009
7	Testosterone (Sustanon)FDA Link 04/2013 - 04/2011
6	CreatinineIBA 10/2023 - 07/2013
6	Sex Hormone-Binding GlobulinIBA 04/2013 - 04/2009
5	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2021
5	Indicators and Reagents (Reagents)IBA 01/2022 - 04/2010
4	Hemoglobins (Hemoglobin)IBA 10/2023 - 06/2013
4	Estradiol (Delestrogen)FDA LinkGeneric 04/2013 - 11/2011
3	Proteins (Proteins, Gene)FDA Link 05/2024 - 11/2020
3	SteroidsIBA 04/2013 - 04/2011
2	Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric 09/2023 - 01/2022
2	RNA (Ribonucleic Acid)IBA 02/2022 - 01/2022
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 08/2016
2	Axitinib (AG 013736)IBA 10/2021 - 01/2021
2	cabozantinibIBA 10/2021 - 01/2021
2	Complement System Proteins (Complement)IBA 10/2021 - 10/2010
2	IpilimumabIBA 10/2021 - 01/2021
2	NivolumabIBA 10/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2009
2	VaccinesIBA 01/2018 - 06/2015
2	Gonadal Steroid Hormones (Sex Hormones)IBA 08/2012 - 08/2011
2	Dihydrotachysterol (AT 10)IBA 12/2009 - 02/2009
2	isopropyl cyanoacrylateIBA 03/2009 - 08/2008
1	drospirenone and ethinyl estradiol combination (Yasmin)FDA LinkGeneric 10/2022
1	Death Domain ReceptorsIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	ChemokinesIBA 01/2022
1	G250 monoclonal antibodyIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	acceleratory factor from growth hormone (AcG)IBA 01/2022
1	Interleukin-1 (Interleukin 1)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 12/2021

Therapy/Procedure

116	Nephrectomy 04/2024 - 11/2008
44	Therapeutics 05/2024 - 08/2008
42	Prostatectomy (Retropubic Prostatectomy) 07/2020 - 07/2008
35	Lymph Node Excision (Lymph Node Dissection) 06/2023 - 04/2008
22	Cystectomy 10/2021 - 01/2009
10	Radiotherapy 05/2024 - 02/2009
8	Thrombectomy 12/2021 - 11/2016
7	Immunotherapy 11/2023 - 01/2020
7	Warm Ischemia 10/2022 - 10/2018
7	Nephroureterectomy 01/2022 - 03/2010
6	Length of Stay 10/2023 - 01/2018
6	Drug Therapy (Chemotherapy) 01/2022 - 04/2008
5	Blood Transfusion (Blood Transfusions) 10/2023 - 12/2020
5	Operative Time 11/2022 - 10/2018
4	Minimally Invasive Surgical Procedures 11/2022 - 08/2019
4	Metastasectomy 12/2019 - 06/2013
3	Neoadjuvant Therapy 01/2022 - 01/2021
3	Aftercare (After-Treatment) 01/2021 - 02/2016
3	Adjuvant Chemotherapy 06/2010 - 01/2010
2	Cryosurgery 01/2023 - 01/2020
2	Operative Surgical Procedures 08/2020 - 05/2016
2	Adjuvant Radiotherapy 06/2013 - 03/2009
2	Transurethral Resection of Prostate (TURP) 05/2011 - 08/2009
1	Retreatment 01/2023
1	Ablation Techniques 01/2023
1	Salvage Therapy 12/2021
1	Robotic Surgical Procedures 12/2021